Who are FOLFIFINOX's main competitors?

Direct comparators (same drug class / molecular target / therapeutic area): Dexamethasona, Idarubicine, ARA-C, Methotrexate, SOX Chemotherapy, Dose dense AC followed by T + trastuzumab, CHOP-daclizumab, TAC chemotherapy, Consolidation Chemotherapy.

How often does this brief refresh?

Every 30 minutes from primary sources (FDA, EMA, MHRA, PMDA, ClinicalTrials.gov, USPTO). Subscribe to the RSS feed below for push alerts.

How do I get this as a recurring report?

Subscribe to /feed/ci/folfifinox.xml in any RSS reader (Feedly, Inoreader, NewsBlur). Every regulatory action, trial readout, or patent event lands in your feed automatically.

Last reviewed 2026-06-10 · How we verify

FOLFIFINOX — Competitive Intelligence Brief

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

FOLFIFINOX (FOLFIFINOX) competitive landscape: 6 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: chemotherapy regimen. Area: Oncology.

phase 2 chemotherapy regimen Oncology Small molecule Live · refreshed every 30 min

Target snapshot

FOLFIFINOX (FOLFIFINOX) — AIO-Studien-gGmbH. FOLFIRINOX is a chemotherapy regimen that combines four different drugs to target rapidly dividing cancer cells.

Comparator set (6 drugs)

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

Drug	Generic	Sponsor	Phase	Class	Target
FOLFIFINOX TARGET	FOLFIFINOX	AIO-Studien-gGmbH	phase 2	chemotherapy regimen
Dexamethasona, Idarubicine, ARA-C, Methotrexate	Dexamethasona, Idarubicine, ARA-C, Methotrexate	PETHEMA Foundation	marketed	Combination chemotherapy regimen
SOX Chemotherapy	SOX Chemotherapy	The First Affiliated Hospital with Nanjing Medical University	marketed	Combination chemotherapy regimen
Dose dense AC followed by T + trastuzumab	Dose dense AC followed by T + trastuzumab	Agendia	marketed	Chemotherapy regimen with monoclonal antibody	HER2 receptor (trastuzumab component); DNA/microtubules (chemotherapy components)
CHOP-daclizumab	CHOP-daclizumab	King's College Hospital NHS Trust	marketed	Monoclonal antibody (daclizumab component) combined with chemotherapy regimen	CD25 (IL-2 receptor alpha chain)
TAC chemotherapy	TAC chemotherapy	Agendia	marketed	Chemotherapy regimen (combination)
Consolidation Chemotherapy	Consolidation Chemotherapy	National Cancer Center Affiliate of Vilnius University Hospital Santaros Klinikos	marketed	Combination chemotherapy regimen

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (chemotherapy regimen class)

University Hospital, Grenoble · 2 drugs in this class
Canadian Cancer Trials Group · 1 drug in this class
Centre Georges Francois Leclerc · 1 drug in this class
Changzhou Jinyuan Pharmaceutical Manufacturing Co., Ltd. · 1 drug in this class
French Innovative Leukemia Organisation · 1 drug in this class
AIO-Studien-gGmbH · 1 drug in this class
GlaxoSmithKline · 1 drug in this class
National Research Center for Hematology, Russia · 1 drug in this class
Ospedale Santa Croce-Carle Cuneo · 1 drug in this class
Suzhou Suncadia Biopharmaceuticals Co., Ltd. · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). FOLFIFINOX — Competitive Intelligence Brief. https://druglandscape.com/ci/folfifinox. Accessed 2026-06-10.

Build your own brief

Pick any drug + add comparators:

https://druglandscape.com/ci/{slug} — auto-detected competitors
https://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3 — explicit comparators
Brand names auto-resolve: /ci/keytruda → 301 → /ci/pembrolizumab

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing